title: Poorly differentiated neuroendocrine carcinoma of the pancreas responsive to combination therapy with gemcitabine and S-1.
abstract: Poorly differentiated neuroendocrine carcinoma is a very rare malignancy, but it is characterized by agressive histological features and a poor clinical prognosis. We report a 42-year-old man who had poorly differentiated neuroendocrine carcinoma of the pancreas with multiple liver metastases. We administrated combined chemotherapy with S-1 and gemcitabine. This treatment was efficacious and well tolerated, and then this patient obtained objective partial response for 7 months and survived for 13 months after the diagnosis. This case suggests that S-1 and gemcitabine combination produce beneficial responses for patients with this disease.
authors.affiliation: The Third Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Japan.
authors.forename: Mitsuyoshi
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Koichiro
authors.initials: K
authors.lastname: Miyagawa
authors.forename: Masaaki
authors.initials: M
authors.lastname: Hiura
authors.forename: Masashi
authors.initials: M
authors.lastname: Taguchi
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Kihara
authors.forename: Shintaro
authors.initials: S
authors.lastname: Abe
authors.forename: Shohei
authors.initials: S
authors.lastname: Shimajiri
authors.forename: Masaru
authors.initials: M
authors.lastname: Harada
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018278:Carcinoma, Neuroendocrine / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004338:Drug Combinations; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D008297:Male; D010094:Oxonic Acid / Q000008:administration & dosage; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D004338:Drug Combinations; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000093542:Gemcitabine